Skip to content

Precision oncology

NeoPainel Somático: comprehensive genomic profiling of the tumor.

A test of the tumor's DNA that can help the doctor choose the treatment. It analyzes 560 genes in a tumor sample already removed in the biopsy or surgery.

NeoPainel Somático report

For patients and families

The test in plain words.

A test of the tumor's DNA can help your doctor choose the most suitable treatment.

What does this test look for in the tumor?

DNA is the instruction manual of our cells. Each gene is a chapter. The test reads 560 genes and looks for changes that can make the tumor grow.

Somatic means “from the tumor”: the test looks for changes that arose in it. It is a test for people who have already been diagnosed with cancer, not a prevention test.

How can the test help with my treatment?

  • Targeted therapyMedicines that act on a specific change in the tumor. The test can guide the choice.

  • ImmunotherapyIt activates the body's defenses. The test can help assess whether it is an option.

  • Clinical trialsResearch studies with new treatments. With the test, your doctor can look for one of them.

  • Knowing the tumorSome changes help the doctor understand the type and the behavior of the tumor.

Is it suitable for my type of cancer? It depends on the type of tumor and the stage of treatment. Your doctor is the one who assesses this.

Will a medicine always show up for me?

Not always.

Not every change has a medicine. If none shows up, that does not rule out other treatments your doctor may recommend. Your doctor reviews the result and decides with you.

The options depend on the tumor type and on the medicines approved in Brazil for it.

What do I receive?

A report with the changes found in the tumor and what each one may mean for treatment. Take it to your appointment: your doctor explains the result and decides the next steps with you.

See a sample report

How is the test done?

  1. 01

    Medical order

    Your doctor orders the test. Without the order, the test is not performed.

  2. 02

    Tumor sample

    The test uses the material already removed in the biopsy or surgery. It is kept by the laboratory that analyzed the biopsy. In general, another biopsy is not needed.

  3. 03

    Our team guides you

    We explain to you or your doctor how to request this material and send it, and check beforehand whether it is suitable for the test.

  4. 04

    Result

    Up to 15 calendar days after the sample reaches our laboratory and is accepted.

Calendar days include Saturdays, Sundays and public holidays. The time needed to gather and send the material comes before that and is not included in this count.

How do I arrange the test? Does my health plan cover it?

Talk to our team on WhatsApp or at 0800 080 0420. They will tell you about the documents, the costs and the payment options.

Health plan coverage depends on your contract, your doctor's indication and the plan's authorization.

See the health plan coverage criteria

Can my cancer run in the family?

This test analyzes only the tumor. It does not assess whether the cancer may run in the family. For that, your doctor may recommend another test, such as Neo360.

  • NeoPainel Somático: analyzes only the tumor.
  • Neo360: analyzes the tumor, the risk of cancer in the family and how your body handles some medicines.
Learn about Neo360

What to do now

  1. Take this question to your appointment

    “NeoPainel Somático or Neo360: is either one right for me?”

  2. With your doctor's order, talk to our team.

    They will guide you on the documents, the material and the payment.

The report informs. Your doctor decides with you.

Questions about the test or the sample? Talk to our team.

Accepted samples
Tumor tissue in paraffin (FFPE) (preferred), Extracted DNA
Turnaround time and when it starts
15 calendar days, after acceptance of the sample
Medical order
Required. View requirements and limitations.

Clinical indication

When should this test be considered?

When the physician needs to investigate molecular alterations in the tumor that may inform treatment selection, diagnostic interpretation or assessment of clinical trials. The indication depends on the tumor type and clinical question.

Discuss the indication

Clinical scope

Sequence, copy number, fusions and biomarkers.

Alteration classes that often require separate tests are assessed in the same assay, from DNA extracted from tumor tissue.

01 / Alterations

Three classes of DNA alteration

Sequence variants, copy number alterations and fusions or rearrangements detectable in DNA, within the regions captured by the panel.

560 genes analyzed.

02 / Biomarkers

TMB and MSI in the same report

Tumor mutational burden is calculated over the coding region with adequate coverage in the sample itself. Microsatellite instability is assessed at dedicated panel loci.

03 / Interpretation

Classification by clinical relevance1

Alterations are classified according to AMP/ASCO/CAP guidelines to support decisions on targeted therapies, immunotherapy and clinical trials.

Clinical use

How the result supports clinical decisions.

The result should be interpreted by the treating physician together with clinical and histopathological data. Therapy selection depends on tumor type, current regulatory approvals and clinical judgment.

  1. 01

    Targeted therapies

    Identification of alterations that may guide the choice of targeted therapies, according to tumor type.

  2. 02

    Immunotherapy

    TMB and MSI are among the biomarkers considered when evaluating immunotherapy.

  3. 03

    Clinical trials

    Molecular alterations that may be targeted by treatments being tested in clinical trials.

  4. 04

    Diagnosis and prognosis

    Alterations with diagnostic or prognostic significance, depending on the tumor context.

Explore the report

From finding to interpretation.

Understand the questions each part of the result helps answer.

NeoPainel SomáticoReading guide

The report format may vary according to the findings and modules assessed.

01 / Tumor profile

What can be found?

Tumor mutational burden (TMB)
Counts somatic mutations per megabase. It can help assess whether the patient is a candidate for immunotherapy.
Microsatellite instability (MSI)
Shows whether the tumor is stable (MSS) or unstable (MSI-H). It can help assess whether the patient is a candidate for immunotherapy.
Sequence variants
Point mutations and small insertions or deletions. Depending on the gene and tumor type, they can point to a targeted therapy or have diagnostic or prognostic value.
Copy number
Gene amplifications or losses. Depending on the gene and tumor type, they can point to a targeted therapy or have prognostic value.
Fusions and rearrangements
Abnormal joins between two genes, assessed in DNA. Some have an associated targeted therapy; others help define the tumor's diagnosis.

How to read this result

Does an alteration mean a treatment option?

Not every finding has an associated therapy. The physician assesses the evidence, diagnosis and options available for that patient.

How are alterations classified?

Under the AMP/ASCO/CAP guidelines, by the evidence of therapeutic, diagnostic or prognostic significance: Tier I, strong clinical significance; Tier II, potential clinical significance; Tier III, unknown significance.

What if no target is identified?

The absence of a reported target does not rule out other care options. The result must be interpreted within the scope and limitations of the test.

Scope and limits

Broad scope with explicit limitations.

The panel covers the coding regions of 560 cancer-associated genes, with additional content for fusions, copy number and microsatellites.

The analysis considers

  • SNVs, indels and multinucleotide variants in the coding regions of 560 genes.
  • Copy number alterations, with additional probes in 58 genes.
  • DNA fusions and rearrangements, from intronic regions of 14 genes: ALK, BCR, BRAF, EGFR, ETV6, EWSR1, FGFR2, FGFR3, NTRK1, NUTM1, PAX8, RET, ROS1 and TMPRSS2.
  • Tumor mutational burden (TMB) and microsatellite instability (MSI).

High-depth sequencing (above 500x), with a detection limit of 3% VAF in samples with tumor content above 30%.

Important limitations

A tumor profile, not a hereditary analysis.

  • The analysis is performed without a matched normal sample: germline variants may not be reliably distinguished from somatic ones.
  • Sensitivity depends on the tumor cell fraction, DNA quantity and quality, and the coverage obtained.
Learn about Neo360, which includes germline analysis

Panel content

The 560 genes analyzed.

HGNC-approved gene symbols in alphabetical order, according to the current technical content of the panel.

See the full gene list

ABL1ABL2ABRAXAS1ACVR1ACVR2AADGRA2AFF3AKT1AKT2AKT3ALKALOX12BAMER1ANKRD11ANKRD26APCARARAFARID1AARID1BARID2ARID5BASXL1ASXL2ATAD5ATF1ATMATRATRXAURKAAURKBAXIN1AXIN2AXLB2MBAP1BARD1BBC3BCL10BCL2BCL2L1BCL2L11BCL6BCORBCORL1BCRBIRC3BLMBMPR1ABRAFBRCA1BRCA2BRD3BRD4BRIP1BTG1BTKCALRCAMTA1CARD11CASP8CBFBCBLCCND1CCND2CCND3CCNE1CD274CD276CD74CD79ACD79BCDC73CDH1CDK12CDK4CDK6CDK8CDKN1ACDKN1BCDKN2ACDKN2BCDKN2CCEBPACENPACHD2CHD4CHEK1CHEK2CICCNBD1CNTNAP2COP1CREBBPCRKLCRLF2CSF1RCSF3RCSMD3CSNK1A1CTCFCTLA4CTNNA1CTNNA2CTNNB1CTNND2CUL3CUX1CXCR4CYLDDAXXDCCDDB2DDR2DDX41DICER1DIS3DNAJB1DNMT1DNMT3ADNMT3BDOT1LDROSHAE2F3EEDEGFL7EGFREIF1AXEIF4A2EIF4EELOCEML4EMSYEP300EPAS1EPCAMEPHA3EPHA5EPHA7EPHB1ERBB2ERBB3ERBB4ERCC1ERCC2ERCC3ERCC4ERCC5ERGERRFI1ESR1ETV1ETV4ETV5ETV6EWSR1EZH2FANCAFANCBFANCCFANCD2FANCEFANCFFANCGFANCIFANCLFANCMFASFAT1FAT3FBXW7FGF1FGF10FGF12FGF14FGF19FGF2FGF23FGF3FGF4FGF5FGF6FGF7FGF8FGF9FGFR1FGFR2FGFR3FGFR4FHFHITFIP1L1FLCNFLT1FLT3FLT4FOXA1FOXL2FOXO1FOXP1FRS2FUBP1FYNGABRA6GATA1GATA2GATA3GATA4GATA6GEN1GID4GLI1GNA11GNA13GNAQGNASGPC5GPS2GREM1GRIN2AGRM3GSK3BH1-2H2BC5H3-3AH3-3BH3-4H3-5H3C10H3C11H3C12H3C13H3C15H3C2H3C3H3C4H3C6H3C7H3C8HGFHLA-AHLA-BHLA-CHNF1AHNRNPKHOXB13HRASHSD3B1HSP90AA1ICOSLGID3IDH1IDH2IFNGR1IGF1IGF1RIGF2IKBKEIKZF1IL10IL7RINHAINHBAINPP4AINPP4BINSRIRF2IRF4IRS1IRS2JAK1JAK2JAK3JUNKAT6AKDM5AKDM5CKDM6AKDRKEAP1KELKIF5BKITKLF4KLHL6KMT2AKMT2BKMT2CKMT2DKRASLAMP1LATS1LATS2LMO1LRP1BLYNLZTR1MAD2L2MAGI2MALAT1MALT1MAP2K1MAP2K2MAP2K4MAP3K1MAP3K13MAP3K14MAPK1MAPK3MAXMCL1MDC1MDM2MDM4MED12MEF2BMEN1METMGAMITFMLH1MLH3MLLT3MPLMRE11MSH2MSH3MSH4MSH5MSH6MST1MST1RMTAPMTORMUC16MUTYHMYBMYCMYCLMYCNMYD88MYOD1NAB2NBEANBNNCOA3NCOR1NEGR1NF1NF2NFE2L2NFKBIANKX2-1NKX3-1NOTCH1NOTCH2NOTCH3NOTCH4NPM1NRASNRG1NSD1NSD2NSD3NTRK1NTRK2NTRK3NUP93NUTM1PAK1PAK3PAK5PALB2PARP1PARP2PARP3PAX3PAX5PAX7PAX8PBRM1PDCD1PDCD1LG2PDGFBPDGFRAPDGFRBPDK1PDPK1PGRPHF6PHOX2BPIK3C2APIK3C2BPIK3C2GPIK3C3PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIM1PLCG2PLK2PMAIP1PMS1PMS2PNRC1POLD1POLEPPARGPPM1DPPP2R1APPP2R2APPP6CPRDM1PREX2PRKAR1APRKCIPRKDCPRKNPRSS8PSIP1PTCH1PTENPTPN11PTPRDPTPRSPTPRTQKIRAB35RAC1RAD21RAD50RAD51RAD51BRAD51CRAD51DRAD52RAD54LRAF1RANBP2RARARASA1RB1RBM10RECQLRECQL4RELRETRGS7RHEBRHOARICTORRIT1RNF43ROBO1ROBO2ROS1RPS6KA4RPS6KB1RPS6KB2RPTORRUNX1RUNX1T1RYBPSDHASDHAF2SDHBSDHCSDHDSETBP1SETD2SF3B1SH2B3SH2D1ASHQ1SLIT2SLX4SMAD2SMAD3SMAD4SMARCA4SMARCB1SMARCD1SMC1ASMC3SMOSNCAIPSOCS1SOX10SOX17SOX2SOX9SPENSPOPSPTA1SRCSRSF2STAG1STAG2STAT3STAT4STAT5ASTAT5BSTK11STK40SUFUSUZ12SYKTAF1TBX3TCF3TCF7L2TEKTENT5CTERCTERTTET1TET2TFE3TFRCTGFBR1TGFBR2TMEM127TMPRSS2TNFAIP3TNFRSF14TOP1TOP2ATP53TP63TRAF2TRAF7TRRAPTSC1TSC2TSHRU2AF1VAV1VEGFAVHLVTCN1WRNWT1XIAPXPO1XRCC1XRCC2XRCC3XRCC5YAP1YES1ZBTB2ZBTB7AZFHX3ZNF217ZNF703ZRSR2

Choice of test

NeoPainel Somático or Neo360?

Both use the 560-gene tumor panel. Neo360 adds paired tumor–normal comparison, hereditary predisposition and pharmacogenomics. The choice depends on the clinical questions to investigate.

Feature NeoPainel Somático Neo360Learn about Neo360
Tumor–normal comparisonTumor sample onlyPaired analysis from the same patient
SamplesTumor: paraffin block (FFPE) or extracted DNATumor and germline sample: blood, buccal swab or DNA
Somatic tumor profile560 genes, TMB and MSI560 genes, TMB and MSI
Hereditary cancer predispositionNot included106 genes, from whole-genome sequencing
PharmacogenomicsNot included6 genes and 12 drugs
ReportSomatic tumor profileIntegrated report in three parts
NeoPainel Somático
Tumor–normal comparison
NeoPainel SomáticoTumor sample only
Neo360Paired analysis from the same patient
Samples
NeoPainel SomáticoTumor: paraffin block (FFPE) or extracted DNA
Neo360Tumor and germline sample: blood, buccal swab or DNA
Somatic tumor profile
NeoPainel Somático560 genes, TMB and MSI
Neo360560 genes, TMB and MSI
Hereditary cancer predisposition
NeoPainel SomáticoNot included
Neo360106 genes, from whole-genome sequencing
Pharmacogenomics
NeoPainel SomáticoNot included
Neo3606 genes and 12 drugs
Report
NeoPainel SomáticoSomatic tumor profile
Neo360Integrated report in three parts

Why germline analysis matters: an alteration found in the tumor may also be present in the normal sample; that is, it may be germline. In Neo360, comparing the two samples helps distinguish germline variants from alterations acquired by the tumor. Neo360 also assesses 106 hereditary predisposition genes, an assessment that may identify a hereditary cancer risk, with possible implications for relatives. Germline findings should be discussed in the context of clinical care and genetic counseling.

How to order

Prepare the order and samples.

Our team provides guidance on documentation and shipping before analysis.

  1. 01

    Gather the clinical information

    Medical order, tumor type, and clinical and histopathological information.

  2. 02

    Confirm the material before shipping

    Ask the team about quantity, preservation, identification and acceptance criteria for the available material.

    • Tumor tissue in paraffin (FFPE)(preferred)
    • Extracted DNA
    View technical requirements
  3. 03

    Arrange logistics and track progress

    Turnaround starts after sample acceptance, according to the test conditions.

Documentation and references

Information for the care team.

Review the test method, scope and limitations. Interpretation references do not replace the specific technical documentation of the assay.

Frequently asked questions

Before requesting the test.

What sample is needed?

A paraffin block (FFPE) with tumor tissue or DNA extracted from tumor tissue. Our team provides guidance on shipping the sample.

Does the test identify hereditary cancer?

That is not its purpose. The test analyzes only the tumor sample, without a matched normal sample, and germline variants may not be reliably distinguished. Suggestive findings in predisposition genes should be confirmed in a non-tumor sample, with genetic counseling. Neo360 includes germline analysis.

What do TMB and MSI mean?

TMB estimates the number of somatic mutations per megabase. MSI assesses microsatellite instability. Results must be interpreted with the assay limitations and clinical context; they are not directly interchangeable between methods.

Does the test detect any gene fusion?

No. Fusions and rearrangements are assessed in DNA, in the captured intronic regions of 14 genes. The test does not assess transcript expression and does not replace RNA, FISH or immunohistochemistry analysis when indicated.

When will the report be ready?

15 calendar days, after acceptance of the sample.

Does the test require a medical request?

Yes. The tumor type and the clinical and histopathological data guide the analysis and the interpretation of the alterations found.

Test information

Technical details for NeoPainel Somático

Method, scope, requirements and limitations

Comprehensive genomic profiling of the tumor: somatic alterations in 560 cancer-associated genes, plus TMB and MSI, from tumor tissue DNA.

Applications
Precision oncology
Accepted samples
Tumor tissue in paraffin (FFPE) (preferred), Extracted DNA
Estimated turnaround time
15 calendar days, after acceptance of the sample
Methodology
Hybrid capture of tumor DNA, followed by high-depth next-generation sequencing (above 500x). Bioinformatic analysis is performed with the NeoSoma CGP v1.0 pipeline. Detection limit: variant allele frequency (VAF) of 3%, in samples with tumor content above 30%. Alterations are classified according to AMP/ASCO/CAP guidelines (2017).
Analytical scope
Coding regions of 560 cancer-associated genes, selected intronic regions for rearrangement detection in 14 genes (ALK, BCR, BRAF, EGFR, ETV6, EWSR1, FGFR2, FGFR3, NTRK1, NUTM1, PAX8, RET, ROS1 and TMPRSS2), additional copy number probes in 58 genes and microsatellite loci. Assesses SNVs, indels and multinucleotide variants, copy number alterations, DNA fusions and rearrangements, TMB and MSI.
Genes analyzed

560 genes analyzed.

See full content

ABL1, ABL2, ABRAXAS1, ACVR1, ACVR2A, ADGRA2, AFF3, AKT1, AKT2, AKT3, ALK, ALOX12B, AMER1, ANKRD11, ANKRD26, APC, AR, ARAF, ARID1A, ARID1B, ARID2, ARID5B, ASXL1, ASXL2, ATAD5, ATF1, ATM, ATR, ATRX, AURKA, AURKB, AXIN1, AXIN2, AXL, B2M, BAP1, BARD1, BBC3, BCL10, BCL2, BCL2L1, BCL2L11, BCL6, BCOR, BCORL1, BCR, BIRC3, BLM, BMPR1A, BRAF, BRCA1, BRCA2, BRD3, BRD4, BRIP1, BTG1, BTK, CALR, CAMTA1, CARD11, CASP8, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD274, CD276, CD74, CD79A, CD79B, CDC73, CDH1, CDK12, CDK4, CDK6, CDK8, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CEBPA, CENPA, CHD2, CHD4, CHEK1, CHEK2, CIC, CNBD1, CNTNAP2, COP1, CREBBP, CRKL, CRLF2, CSF1R, CSF3R, CSMD3, CSNK1A1, CTCF, CTLA4, CTNNA1, CTNNA2, CTNNB1, CTNND2, CUL3, CUX1, CXCR4, CYLD, DAXX, DCC, DDB2, DDR2, DDX41, DICER1, DIS3, DNAJB1, DNMT1, DNMT3A, DNMT3B, DOT1L, DROSHA, E2F3, EED, EGFL7, EGFR, EIF1AX, EIF4A2, EIF4E, ELOC, EML4, EMSY, EP300, EPAS1, EPCAM, EPHA3, EPHA5, EPHA7, EPHB1, ERBB2, ERBB3, ERBB4, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, ERG, ERRFI1, ESR1, ETV1, ETV4, ETV5, ETV6, EWSR1, EZH2, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FAS, FAT1, FAT3, FBXW7, FGF1, FGF10, FGF12, FGF14, FGF19, FGF2, FGF23, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, FGFR1, FGFR2, FGFR3, FGFR4, FH, FHIT, FIP1L1, FLCN, FLT1, FLT3, FLT4, FOXA1, FOXL2, FOXO1, FOXP1, FRS2, FUBP1, FYN, GABRA6, GATA1, GATA2, GATA3, GATA4, GATA6, GEN1, GID4, GLI1, GNA11, GNA13, GNAQ, GNAS, GPC5, GPS2, GREM1, GRIN2A, GRM3, GSK3B, H1-2, H2BC5, H3-3A, H3-3B, H3-4, H3-5, H3C10, H3C11, H3C12, H3C13, H3C15, H3C2, H3C3, H3C4, H3C6, H3C7, H3C8, HGF, HLA-A, HLA-B, HLA-C, HNF1A, HNRNPK, HOXB13, HRAS, HSD3B1, HSP90AA1, ICOSLG, ID3, IDH1, IDH2, IFNGR1, IGF1, IGF1R, IGF2, IKBKE, IKZF1, IL10, IL7R, INHA, INHBA, INPP4A, INPP4B, INSR, IRF2, IRF4, IRS1, IRS2, JAK1, JAK2, JAK3, JUN, KAT6A, KDM5A, KDM5C, KDM6A, KDR, KEAP1, KEL, KIF5B, KIT, KLF4, KLHL6, KMT2A, KMT2B, KMT2C, KMT2D, KRAS, LAMP1, LATS1, LATS2, LMO1, LRP1B, LYN, LZTR1, MAD2L2, MAGI2, MALAT1, MALT1, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MAP3K13, MAP3K14, MAPK1, MAPK3, MAX, MCL1, MDC1, MDM2, MDM4, MED12, MEF2B, MEN1, MET, MGA, MITF, MLH1, MLH3, MLLT3, MPL, MRE11, MSH2, MSH3, MSH4, MSH5, MSH6, MST1, MST1R, MTAP, MTOR, MUC16, MUTYH, MYB, MYC, MYCL, MYCN, MYD88, MYOD1, NAB2, NBEA, NBN, NCOA3, NCOR1, NEGR1, NF1, NF2, NFE2L2, NFKBIA, NKX2-1, NKX3-1, NOTCH1, NOTCH2, NOTCH3, NOTCH4, NPM1, NRAS, NRG1, NSD1, NSD2, NSD3, NTRK1, NTRK2, NTRK3, NUP93, NUTM1, PAK1, PAK3, PAK5, PALB2, PARP1, PARP2, PARP3, PAX3, PAX5, PAX7, PAX8, PBRM1, PDCD1, PDCD1LG2, PDGFB, PDGFRA, PDGFRB, PDK1, PDPK1, PGR, PHF6, PHOX2B, PIK3C2A, PIK3C2B, PIK3C2G, PIK3C3, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIM1, PLCG2, PLK2, PMAIP1, PMS1, PMS2, PNRC1, POLD1, POLE, PPARG, PPM1D, PPP2R1A, PPP2R2A, PPP6C, PRDM1, PREX2, PRKAR1A, PRKCI, PRKDC, PRKN, PRSS8, PSIP1, PTCH1, PTEN, PTPN11, PTPRD, PTPRS, PTPRT, QKI, RAB35, RAC1, RAD21, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RAF1, RANBP2, RARA, RASA1, RB1, RBM10, RECQL, RECQL4, REL, RET, RGS7, RHEB, RHOA, RICTOR, RIT1, RNF43, ROBO1, ROBO2, ROS1, RPS6KA4, RPS6KB1, RPS6KB2, RPTOR, RUNX1, RUNX1T1, RYBP, SDHA, SDHAF2, SDHB, SDHC, SDHD, SETBP1, SETD2, SF3B1, SH2B3, SH2D1A, SHQ1, SLIT2, SLX4, SMAD2, SMAD3, SMAD4, SMARCA4, SMARCB1, SMARCD1, SMC1A, SMC3, SMO, SNCAIP, SOCS1, SOX10, SOX17, SOX2, SOX9, SPEN, SPOP, SPTA1, SRC, SRSF2, STAG1, STAG2, STAT3, STAT4, STAT5A, STAT5B, STK11, STK40, SUFU, SUZ12, SYK, TAF1, TBX3, TCF3, TCF7L2, TEK, TENT5C, TERC, TERT, TET1, TET2, TFE3, TFRC, TGFBR1, TGFBR2, TMEM127, TMPRSS2, TNFAIP3, TNFRSF14, TOP1, TOP2A, TP53, TP63, TRAF2, TRAF7, TRRAP, TSC1, TSC2, TSHR, U2AF1, VAV1, VEGFA, VHL, VTCN1, WRN, WT1, XIAP, XPO1, XRCC1, XRCC2, XRCC3, XRCC5, YAP1, YES1, ZBTB2, ZBTB7A, ZFHX3, ZNF217, ZNF703, ZRSR2

Medical order
Required
Requirements
Medical order with the tumor type and the clinical and histopathological information. A paraffin block (FFPE) with tumor tissue or DNA extracted from tumor tissue.
Limitations

Analysis of the tumor sample only, without a matched normal sample: germline variants may not be reliably distinguished from somatic ones. Variants with an allele frequency near 50% or 100% in hereditary cancer predisposition genes should be confirmed in a non-tumor sample, with genetic counseling.

Sensitivity depends on the tumor cell fraction, DNA quantity and quality, and the coverage obtained. Samples with low tumor fraction or degraded DNA may yield false-negative results, especially for low-allele-frequency subclonal variants and for copy number alterations.

Formalin fixation may cause sequencing artifacts; low-allele-frequency variants are interpreted with caution.

Fusions and rearrangements are assessed only in DNA and in the captured intronic regions: the test does not detect every possible fusion, does not assess transcript expression and does not replace RNA, FISH or immunohistochemistry analysis when indicated.

Copy number alterations are assessed at higher resolution in genes with probe enrichment; small deletions, low-coverage regions and low-level gains may not be detected.

TMB and MSI are estimates obtained from a gene panel; their values are not directly interchangeable with those of other methods or panels.

The test does not assess epigenetic alterations, variants outside the captured regions, repeat expansions or balanced rearrangements outside the target regions.

Additional information
Clinical classification reflects the scientific knowledge available on the report release date and may be revised. The result should be interpreted by the treating physician together with clinical and histopathological data; therapy selection depends on tumor type, current regulatory approvals and clinical judgment.

Next step

Discuss the case with our team.

We provide guidance on the sample, documentation and limits of NeoPainel Somático before shipment.

Turnaround time and when it starts
15 calendar days, after acceptance of the sample
Medical order
Required

PatientsPatient area Test results

  1. Clinical classification reflects the scientific knowledge available on the report release date and may be revised.